与M2蛋白胞外域相比,血凝素融合肽诱导的甲型流感病毒异亚型保护性免疫。
Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein.
作者信息
Staneková Z, Király J, Stropkovská A, Mikušková T, Mucha V, Kostolanský F, Varečková E
机构信息
Slovak Academy of Sciences, Bratislava, Slovak Republic.
出版信息
Acta Virol. 2011;55(1):61-7. doi: 10.4149/av_2011_01_61.
Several types of influenza vaccines are available, but due to the highly unpredictable variability of influenza virus surface antigens (hemagglutinin (HA) and neuraminidase) current vaccines are not sufficiently effective against broad spectrum of the influenza viruses. An innovative approach to extend the vaccine efficacy is based on the selection of conserved influenza proteins with a potential to induce inter-subtype protection against the influenza A viruses. A promising new candidate for the preparation of broadly protective vaccine may be a highly conserved N-terminal part of HA2 glycopolypeptide (HA2 gp) called fusion peptide. To study its capacity to induce a protective immune response, we immunized mice with the fusion peptide (aa 1-38 of HA2 gp). The protective ability of fusion peptide was compared with the ectodomain aa 2-23 of M2 protein (eM2) that is antigenically conserved and its immunogenic properties have already been well documented. Corresponding peptides (both derived from A/Mississippi/1/85 (H3N2) virus) were synthesized and conjugated to the keyhole limpet hemocyanin (KLH) and used for the immunization of mice. Both antigens induced a significant level of specific antibodies. Immunized mice were challenged with the lethal dose of homologous (H3N2) or heterologous A/PR/8/34 (H1N1) influenza A viruses. Immunization with the fusion peptide led to the 100% survival of mice infected with 1 LD50 of homologous as well as heterologous virus. Survival rate decreased when infectious dose was raised to 2 LD50. The immunization with eM2 induced effective cross-protection of mice infected even with 3 LD50 of both challenge viruses. The lower, but still effective protection induced by the fusion peptide of HA2 gp suggested that besides ectodomain of M2, fusion peptide could also be considered as a part of cross-protective influenza vaccine. To our knowledge, this is the first report demonstrating that active immunization with the conjugated fusion peptide of HA2 gp provided the effective production of antibodies, what contributed to the cross-protection against influenza infection.
有几种类型的流感疫苗可供使用,但由于流感病毒表面抗原(血凝素(HA)和神经氨酸酶)具有高度不可预测的变异性,目前的疫苗对广泛的流感病毒的有效性不足。一种扩展疫苗效力的创新方法是基于选择具有诱导针对甲型流感病毒亚型间保护潜力的保守流感蛋白。制备广泛保护性疫苗的一个有前景的新候选物可能是HA2糖多肽(HA2 gp)的高度保守的N端部分,称为融合肽。为了研究其诱导保护性免疫反应的能力,我们用融合肽(HA2 gp的第1至38位氨基酸)免疫小鼠。将融合肽的保护能力与M2蛋白的胞外域第2至23位氨基酸(eM2)进行比较,M2蛋白在抗原性上是保守的,其免疫原性特性已经有充分的文献记载。合成了相应的肽(均来源于A/密西西比/1/85(H3N2)病毒)并与钥孔血蓝蛋白(KLH)偶联,用于免疫小鼠。两种抗原均诱导产生了显著水平的特异性抗体。用致死剂量的同源(H3N2)或异源A/PR/8/34(H1N1)甲型流感病毒攻击免疫的小鼠。用融合肽免疫导致感染1个半数致死剂量(LD50)同源和异源病毒的小鼠100%存活。当感染剂量提高到2个LD50时,存活率下降。用eM2免疫可有效交叉保护感染高达3个LD50两种攻击病毒的小鼠。HA2 gp融合肽诱导的较低但仍然有效的保护表明,除了M2的胞外域,融合肽也可被视为交叉保护性流感疫苗的一部分。据我们所知,这是第一份证明用HA2 gp偶联融合肽进行主动免疫可有效产生抗体,从而有助于对流感感染进行交叉保护的报告。